title: Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease.
abstract: BACKGROUND
  To evaluate the impact of the extent of coronary disease (single- or multivessel) and of fluvastatin treatment on the incidence of long-term cardiac atherosclerotic complications in the Lescol Intervention Prevention Study (LIPS).
  
  
  METHODS
  A total of 1063 patients with single-vessel disease and 614 patients with multivessel disease were randomized to receive fluvastatin (40 mg bid) or placebo for at least 3 years following a first successful percutaneous coronary intervention. The incidence of cardiac atherosclerotic events (cardiac death, non-fatal myocardial infarction, and coronary re-interventions not related to restenosis) was evaluated.
  
  
  RESULTS
  Patients with multivessel disease tended to be older and presented a higher prevalence of associated risk factors and cardiovascular antecedents. The presence of multivessel disease markedly increased the risk of cardiac atherosclerotic events compared with single-vessel disease among patients allocated to placebo (RR 1.67 [95% CI: 1.24-2.25]; p<0.001). In patients treated with fluvastatin, however, no significant differences in long-term outcomes were observed between patients with multivessel disease and patients single-vessel disease (RR 1.28 [95% CI: 0.90-1.81]; p=0.2).
  
  
  CONCLUSIONS
  Multivessel coronary disease impaired the 4-year outcomes after percutaneous intervention. However, the hazardous effect of multivessel disease was significantly reduced by long-term fluvastatin treatment.
authors.affiliation: Erasmus Medical Center, Thoraxcenter, Rotterdam, Netherlands.
authors.forename: Pedro A
authors.initials: PA
authors.lastname: Lemos
authors.forename: Pim J
authors.initials: PJ
authors.lastname: de Feyter
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Francesco
authors.initials: F
authors.lastname: Saia
authors.forename: Chourmouzios A
authors.initials: CA
authors.lastname: Arampatzis
authors.forename: Clemens
authors.initials: C
authors.lastname: Disco
authors.forename: Nestor
authors.initials: N
authors.lastname: Mercado
authors.forename: Vicente
authors.initials: V
authors.lastname: Mainar
authors.forename: César
authors.initials: C
authors.lastname: Morís
authors.forename: A A
authors.initials: AA
authors.lastname: van den Bos
authors.forename: Gunnar
authors.initials: G
authors.lastname: Berghoefer
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D003324:Coronary Artery Disease / Q000453:epidemiology; D003327:Coronary Disease / Q000188:drug therapy* / Q000628:therapy; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use*; D000077340:Fluvastatin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D018570:Risk Assessment; D015607:Stents
chemical_list: D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000077340:Fluvastatin